To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Phase 3 Not yet recruiting 282 enrolled Qilu Pharmaceutical Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.

Timeline

Start: 2025-06
Primary completion: 2027-05
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abaloparatide	Peptide	80 ug	Subcutaneous
Comparator	Teriparatide	Protein / enzyme biologic	20 ug	Subcutaneous

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Summary

Timeline

Drugs

Indications